Concert Pharma

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

Does Concert Pharmaceuticals (CNCE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Concert Pharmaceuticals (CNCE) is a Great Momentum Stock to Buy

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Investor Relations Roger Tung - President and CEO Marc Becker - CFO Nancy Stuart - COO Jim Cassella - Chief Development Officer Conference Call Participants Jason Butler - JMP Securities Leszek Sulewski - Truist Kevin Strang - Jefferies Operator Good day, and thank you for standing by. Welcome to Concert Pharmaceuticals Second Quarter 2021 Financial Results Conference Call.

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2022 Results - Earnings Call Transcript

If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes Concert (CNCE) a Good Fit for "Trend Investing"

The mean of analysts' price targets for Concert (CNCE) points to a 158.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Concert (CNCE) Have the Potential to Rally 158% as Wall Street Analysts Expect?

Concert (CNCE) delivered earnings and revenue surprises of 34.44% and 93.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports second quarter 2022 financial results.

Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert announced positive topline results from its second Phase 3 clinical trial, THRIVE-AA2, evaluating CTP-543 in patients with alopecia areata.

Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022.

Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022

Concert Pharmaceuticals has a JAK inhibitor for alopecia areata (AA) that may be superior to competitive products. The company cites a figure of 1.5m US patients with AA. Published literature cites a prevalence of 700,000 patients and only 300,000 with moderate to severe AA.

Concert Pharmaceuticals: A Balanced Risk/Reward

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY. A webcast of the JMP fireside chat may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for two weeks following the presentation. About Concert Concert Pharmace

Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference

CymaBay Therapeutics

Dakota Gold Corp

Helbiz

Nerdy

Insiders are scooping up these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 2 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy In June According To These Insiders Part 2

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--CTP-543 Phase 2 results in alopecia areata published in JAAD.

Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share. The aggregate gross proceeds to Concert from this offering were $47.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Concert. Concert also announced the receipt of $18.9 million upon the exercise of tra

Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals announces pricing of public offering.

Concert Pharmaceuticals Announces Pricing of Public Offering

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Concert. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies and Truist Securities a

Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert's THRIVE-AA1 Phase 3 study in alopecia areata meets primary endpoint for scalp hair regrowth and key secondary endpoints at both doses.

Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ: CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent.  The '659 patent claims methods of treating hair loss,.

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

RBC Capital analyst Walter Spracklin lowered the price target for CCL Industries Inc (TSX: CCL.B) (OTC: CCDBF) to C$74 from C$80. The analyst maintained the Outperform rating on the shares.

What's Going On With CCL Industries Shares Today

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Investor Relations Roger Tung - Chief Executive Officer Marc Becker - Chief Financial Officer Nancy Stuart - Chief Operating Officer Jim Cassella - Chief Development Officer Conference Call Participants Jason Butler - JMP Securities Vamil Divan - Mizuho Securities Maury Raycroft - Jefferies Les Sulewski - Truist Securities Esther Hong - Berenberg Operator Good day, and thank you for standing by. Welcome to the Concert Pharmaceuticals First Quarter 2022 Investor Update Call.

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2022 Results - Earnings Call Transcript

Concert (CNCE) delivered earnings and revenue surprises of -7.53% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Misses Revenue Estimates

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the first quarter of 2022.

Concert Pharmaceuticals Reports First Quarter 2022 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will report first quarter 2022 financial results before the markets open on May 5, 2022.

Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q4 2021 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the fourth quarter of 2021.

News for Concert Pharma Stock (CNCE)